Skip to main content

DIMA Biotech

DIMA_Biotech

DIMA Biotechnology Ltd. is a biotech company focusing on preclinical R&D products and services for druggable targets. They plan to complete the preparation of lead antibody molecules for all druggable targets in the next 3-5 years. DIMA Biotech provides multiple pre-prepared lead antibody molecules for each target to help pharmaceutical companies skip the tedious steps of monoclonal antibody platform establishment and lead molecule screening. Therefore,  companies can  have more time to focus on the biological mechanism and developability study of drug targets, thus accelerating the process of new drug R&D.

Over the years, DIMA Biotech has been deeply engaged in developing and optimizing the underlying technology platforms for preclinical research. Currently, they have established two independently developed core technology platforms:

Single/multiple transmembrane protein eukaryotic expression, preparation and purification platforms, apply mammalian cell expression systems, provide ECD or full-length membrane protein products closest to native conformation and functional validation. In addition, DIMA Biotech has developed five major functional full-length transmembrane protein preparation systems, including Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Synthetic Nanodisc. Thousands of drug target protein products are in stock. 
DimAb® High-throughput single B-cell lead antibody molecule discovery platform. DIMA Biotech has completed the preparation and screening of lead antibody molecules against more than 200 drug targets by this platform in just two years. Moreover, they have formed strategic partnerships with several international pharmaceutical enterprises and licensed several drug target molecules. DIMA’s preclinical development strength is widely recognized by the industry. 


www.dimabio.com

The prices are on request! Contact Us by e-mail info@sobekbio.com

Starter Bio

starter_bio

STARTER Bio is a professional IVD core materials provider. STARTER Bio’s recombinant proteins, antibodies and other materials have been applied widely in the world. STARTER Bio is dedicated to developing and delivering highly competitive antibodies and proteins for IVD assay development and research applications. With extensive knowledge on core materials development and in-vitro diagnostic assays development, The company's core team has been deeply engaged in antibody research and development for nearly 20 years.
Their products cover many fields, including infectious diseases, tumor biomarkers, cardiac markers, inflammation biomarkers and hormone markers. Those products are applied extensively in top IVD manufacturers in China, US, Japan, EU and other areas.

With the mission of accelerating the diagnosis of human and animal diseases and escorting human and animal health, the company is based on solid science and technology, adhering to the values of integrity and honesty, guided by the needs of industry customers, and is willing to cooperate sincerely with fraternity around the world, Open a new chapter in health.

www.starter-bio.com

The prices are on request! Contact Us by e-mail info@sobekbio.com

Human APRIL Protein, hFc Tag PME100854

PICTO_DIMABiotech.jpg


The add to cart button will appear once you select the values above

Specifications

10µg / 50µg / 100µg

Alternative names:

TNFSF13;CD256;TALL2;ZTNF2;TALL-2;TNLG7B;TRDL-1;UNQ383/PRO715

Description:

Recombinant Human APRIL Protein with N-terminal human Fc tag

Background:

The protein encoded by this gene is a member of the tumor necrosis factor (TNF) ligand family. This protein is a ligand for TNFRSF17/BCMA, a member of the TNF receptor family. This protein and its receptor are both found to be important for B cell development. In vitro experiments suggested that this protein may be able to induce apoptosis through its interaction with other TNF receptor family proteins such as TNFRSF6/FAS and TNFRSF14/HVEM. Alternative splicing results in multiple transcript variants. Some transcripts that skip the last exon of the upstream gene (TNFSF12) and continue into the second exon of this gene have been identified; such read-through transcripts are contained in GeneID 407977, TNFSF12-TNFSF13. [provided by RefSeq, Oct 2010]

Molecular characterization:

hFc(Glu99-Ala330) APRIL(Ala105-Leu250)

Molecular weight:

The protein has a predicted molecular mass of 42.5 kDa after removal of the signal peptide. The apparent molecular mass of hFc-APRIL is approximately 35-55 kDa due to glycosylation.

Tag:

N-Human Fc Tag

Expression host:

HEK293

Target:

APRIL

Purity:

The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining.

Formulation / Reconstitution:

Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.

Storage:

Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

More info:

Email info@sobekbio.com

Orders:

Email orders@sobekbio.com